Inferring a tumor progression model for neuroblastoma from genomic data

被引:32
作者
Bilke, S
Chen, QR
Westerman, F
Schwab, M
Catchpoole, D
Khan, J
机构
[1] NCI, Ctr Adv Technol, Bethesda, MD 20892 USA
[2] NCI, Oncogenom Sect, Pediat Oncol Branch, Ctr Adv Technol, Gaithersburg, MD USA
[3] German Canc Res Ctr, Dept Tumor Genet, D-6900 Heidelberg, Germany
[4] Childrens Hosp, Tumor Bank, Westmead, NSW, Australia
关键词
D O I
10.1200/JCO.2005.03.2821
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The knowledge of the key genomic events that are causal to cancer development and progression not only is invaluable for our understanding of cancer biology but also may have a direct clinical impact. The task of deciphering a model of tumor progression by requiring that it explains (or at least does not contradict) known clinical and molecular evidence can be very demanding, particularly for cancers with complex patterns of clinical and molecular evidence. Materials and Methods We formalize the process of model inference and show how a progression model for neuroblastoma (NB) can be inferred from genomic data. The core idea of our method is to translate the model of clonal cancer evolution to mathematical testable rules of inheritance. Seventy-eight NB samples in stages 1, 4S, and 4 were analyzed with array-based comparative genomic hybridization. Results The pattern of recurrent genomic alterations in NB is strongly stage dependent and it is possible to identify traces of tumor progression in this type of data. Conclusion A tumor progression model for neuroblastoma is inferred, which is in agreement with clinical evidence, explains part of the heterogeneity of the clinical behavior observed for NB, and is compatible with existing empirical models of NB progression.
引用
收藏
页码:7322 / 7331
页数:10
相关论文
共 49 条
[21]   Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas [J].
Guo, C ;
White, PS ;
Weiss, MJ ;
Hogarty, MD ;
Thompson, PM ;
Stram, DO ;
Gerbing, R ;
Matthay, KK ;
Seeger, RC ;
Brodeur, GM ;
Maris, JM .
ONCOGENE, 1999, 18 (35) :4948-4957
[22]  
Hyman E, 2002, CANCER RES, V62, P6240
[23]  
Kaneko Y, 2000, GENE CHROMOSOME CANC, V29, P89, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1021>3.0.CO
[24]  
2-Y
[25]   Cancer-susceptibility genes - Gatekeepers and caretakers [J].
Kinzler, KW ;
Vogelstein, B .
NATURE, 1997, 386 (6627) :761-&
[27]  
Ladenstein R, 2001, MED PEDIATR ONCOL, V36, P83
[28]   CLINICAL RELEVANCE OF TUMOR-CELL PLOIDY AND N-MYC GENE AMPLIFICATION IN CHILDHOOD NEUROBLASTOMA - A PEDIATRIC ONCOLOGY GROUP-STUDY [J].
LOOK, AT ;
HAYES, FA ;
SHUSTER, JJ ;
DOUGLAS, EC ;
CASTLEBERRY, RP ;
BOWMAN, LC ;
SMITH, EI ;
BRODEUR, GM .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :581-591
[29]   Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis [J].
Luttikhuis, MEMO ;
Powell, JE ;
Rees, SA ;
Genus, T ;
Chughtai, S ;
Ramani, P ;
Mann, JR ;
McConville, CM .
BRITISH JOURNAL OF CANCER, 2001, 85 (04) :531-537
[30]   Molecular biology of neuroblastoma [J].
Maris, JM ;
Matthay, KK .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2264-2279